Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-cash Items: 2015-2024

Historic Non-cash Items for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $9.9 million.

  • Seres Therapeutics' Non-cash Items fell 77.27% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 77.27%. This contributed to the annual value of $9.9 million for FY2024, which is 6.08% down from last year.
  • Seres Therapeutics' Non-cash Items amounted to $9.9 million in FY2024, which was down 6.08% from $10.5 million recorded in FY2023.
  • Over the past 5 years, Seres Therapeutics' Non-cash Items peaked at $28.0 million during FY2021, and registered a low of $3.2 million during FY2020.
  • In the last 3 years, Seres Therapeutics' Non-cash Items had a median value of $9.9 million in 2024 and averaged $9.3 million.
  • As far as peak fluctuations go, Seres Therapeutics' Non-cash Items surged by 785.14% in 2021, and later crashed by 73.43% in 2022.
  • Seres Therapeutics' Non-cash Items (Yearly) stood at $3.2 million in 2020, then spiked by 785.14% to $28.0 million in 2021, then plummeted by 73.43% to $7.4 million in 2022, then skyrocketed by 40.95% to $10.5 million in 2023, then dropped by 6.08% to $9.9 million in 2024.